BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
Life science suppliers can use this study to determine research and market areas poised for growth.

ARLINGTON, VA, May 07, 2009 /24-7PressRelease/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts being made to laboratory budgets, the market for stem cell research products is expected to increase substantially over the next several years to $688.9 M in 2009 and just under one billion at the end of 2011. Suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell research products market. In this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current—and planned—areas of stem cell research, usage of stem cell products and preferred suppliers.

Life science suppliers can use this study to determine areas poised for growth (i.e., the market for stem cell culture media, sera, supplements and cell lines) in the stem cell research market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

ATCC
BD Biosciences (a part of Becton, Dickinson and Co., NYSE:BDX)
CellGenix
Life Technologies (NASDAQ: LIFE)
Lonza (SWX: LONN)
Millipore (NYSE: MIL)
Miltenyi Biotec
R&D Systems (division of TECHNE Corp., NASDAQ: TECH)
Sigma-Aldrich (divisions: SAFC Biosciences, NASDAQ: SIAL)
Stem Cell Sciences (AIM: STEM)
Stemcell Technologies
Thermo Fisher Scientific (Hyclone, NYSE: TMO)
Zen Bio


"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise." Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.

Press Release Contact Information:

Mary Follin
BioInformatics, LLC
Marketing/Sales Manager
2111 Wilson Blvd
Arlington, VA
U.S. 22201
Voice: 703.778.3080 ext. 13
Fax: 703.778.3081
Website: Visit Our Website